BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23766361)

  • 1. MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.
    Calura E; Fruscio R; Paracchini L; Bignotti E; Ravaggi A; Martini P; Sales G; Beltrame L; Clivio L; Ceppi L; Di Marino M; Fuso Nerini I; Zanotti L; Cavalieri D; Cattoretti G; Perego P; Milani R; Katsaros D; Tognon G; Sartori E; Pecorelli S; Mangioni C; D'Incalci M; Romualdi C; Marchini S
    Clin Cancer Res; 2013 Aug; 19(15):4114-23. PubMed ID: 23766361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
    Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
    Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.
    Calura E; Paracchini L; Fruscio R; DiFeo A; Ravaggi A; Peronne J; Martini P; Sales G; Beltrame L; Bignotti E; Tognon G; Milani R; Clivio L; Dell'Anna T; Cattoretti G; Katsaros D; Sartori E; Mangioni C; Ardighieri L; D'Incalci M; Marchini S; Romualdi C
    Ann Oncol; 2016 Aug; 27(8):1511-9. PubMed ID: 27194815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer.
    Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Lee YS; Cho YL
    Anticancer Res; 2015 May; 35(5):2611-7. PubMed ID: 25964536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.
    Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Park HJ; Lee YS; Cho YL
    Cancer Genomics Proteomics; 2017; 14(2):137-141. PubMed ID: 28387653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
    Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
    Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.
    Teng Y; Su X; Zhang X; Zhang Y; Li C; Niu W; Liu C; Qu K
    Oncotarget; 2016 Dec; 7(49):81621-81633. PubMed ID: 27835595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.
    Martini P; Paracchini L; Caratti G; Mello-Grand M; Fruscio R; Beltrame L; Calura E; Sales G; Ravaggi A; Bignotti E; Odicino FE; Sartori E; Perego P; Katsaros D; Craparotta I; Chiorino G; Cagnin S; Mannarino L; Ceppi L; Mangioni C; Ghimenti C; D'Incalci M; Marchini S; Romualdi C
    Clin Cancer Res; 2017 May; 23(9):2356-2366. PubMed ID: 27827314
    [No Abstract]   [Full Text] [Related]  

  • 9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma.
    Guo F; Tian J; Lin Y; Jin Y; Wang L; Cui M
    J Int Med Res; 2013 Oct; 41(5):1456-61. PubMed ID: 23963852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
    Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
    Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study.
    Calura E; Ciciani M; Sambugaro A; Paracchini L; Benvenuto G; Milite S; Martini P; Beltrame L; Zane F; Fruscio R; Marchette MD; Borella F; Tognon G; Ravaggi A; Katsaros D; Bignotti E; Odicino F; D'Incalci M; Marchini S; Romualdi C
    Cells; 2019 Dec; 8(12):. PubMed ID: 31805750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features.
    Xu S; Xu P; Wu W; Ou Y; Xu J; Zhang G; Li J; Xu G
    Curr Pharm Des; 2014; 20(11):1888-95. PubMed ID: 23888941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.
    Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
    Microrna; 2020; 9(4):289-294. PubMed ID: 32703147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.
    Cao Q; Lu K; Dai S; Hu Y; Fan W
    Int J Clin Exp Pathol; 2014; 7(5):2392-401. PubMed ID: 24966949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC.
    Zhao H; Ding Y; Tie B; Sun ZF; Jiang JY; Zhao J; Lin X; Cui S
    Int J Oncol; 2013 Sep; 43(3):839-49. PubMed ID: 23787480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
    Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
    Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1.
    Niu K; Shen W; Zhang Y; Zhao Y; Lu Y
    Gene; 2015 Dec; 574(2):330-6. PubMed ID: 26275944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
    Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
    Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer.
    Paudel D; Zhou W; Ouyang Y; Dong S; Huang Q; Giri R; Wang J; Tong X
    Gene; 2016 Jul; 586(1):48-55. PubMed ID: 27048832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.